The use of thiosulfate to increase polymerization of IgM subunits.
Sodium thiosulfate was used to enhance in vivo the polymerization of myeloma IgM, deficient in disulfide cross-links. The therapy sharply decreased the amount of low molecular weight IgM fractions, while increasing the serum content of molecules of higher molecular weight. The degree of disulfide cross-linking in IgM increased under the influence of thiosulfate. The rate of secretion into the serum and urine of some membrane-related glycopeptides and species rich in sialic acid was reduced. Also, the discharge of L chains to the urine was lowered during the thiosulfate trial. All these changes were attributed to enhancement of disulfide-interchanging enzyme activity by thiosulfate.
D001665:Binding Sites; D004220:Disulfides / Q000378:metabolism; D006801:Humans; D007128:Immunoglobulin Fragments / Q000652:urine; D007075:Immunoglobulin M / Q000378:metabolism* / Q000652:urine; D046911:Macromolecular Substances; D008970:Molecular Weight; D011485:Protein Binding; D012794:Sialic Acids / Q000378:metabolism; D013885:Thiosulfates / Q000494:pharmacology / Q000627:therapeutic use*; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
D004220:Disulfides; D007128:Immunoglobulin Fragments; D007075:Immunoglobulin M; D046911:Macromolecular Substances; D012794:Sialic Acids; D013885:Thiosulfates